Cronos Group (CRON) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Cronos Group (CRON) over the past year, gaining 104.5% versus a gain of 20.1%. Over five years, KNSA leads with a +580.9% price change compared with -41.2% for CRON. Kiniksa Pharmaceuticals International is the larger company by market cap ($6.14 billion vs $1.19 billion), about 5.2 times the size.
On valuation, Cronos Group trades at a lower trailing P/E (16.9x vs 79.5x for Kiniksa Pharmaceuticals International).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRON | KNSA |
|---|---|---|
| Share price | $3.22 | $78.75 |
| Market cap | $1.19B | $6.14B |
| 1-day change | -0.62% | +1.01% |
| YTD return | +22.43% | +88.99% |
| 1-year return | +20.15% | +104.51% |
| 5-year return | -41.24% | +580.87% |
| P/E ratio (TTM) | 16.95 | 79.55 |
| Forward P/E | — | 48.69 |
| EPS (TTM) | $0.19 | $0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $677.56M |
| Revenue growth (YoY) | — | +60.09% |
| Net income (latest FY) | — | $59.01M |
| Gross margin | — | 88.54% |
| Operating margin | — | 11.40% |
| Net margin | — | 8.71% |
| 52-week high | $3.61 | $82.94 |
| 52-week low | $2.28 | $35.20 |
| Distance from 52-week high | -10.75% | -5.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | -23.29% | +24.44% |
| Average volume | 1.13M | 578.96K |
| Shares outstanding | 368.41M | 48.29M |
| Employees | 610 | 366 |
| Sector | Healthcare | Health Care |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Kiniksa Pharmaceuticals International is about 5.2 times larger than Cronos Group by market value ($6.14B vs $1.19B).
- KNSA has outperformed CRON by 84.4 percentage points over the past year.
- Kiniksa Pharmaceuticals International trades at a higher earnings multiple (79.5x vs 16.9x trailing P/E).
- The two companies sit in different sectors: Cronos Group in Healthcare and Kiniksa Pharmaceuticals International in Health Care.
About Cronos Group
CRON stock →Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names.
Healthcare · Drug Manufacturers - Specialty & Generic · 610 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
CRON vs KNSA FAQ
Which is bigger, Cronos Group or Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $6.14B compared with $1.19B for Cronos Group (CRON).
Which stock has performed better over the past year, CRON or KNSA?
KNSA returned +104.51% over the past 12 months, compared with +20.15% for CRON (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CRON or KNSA?
CRON has the lower trailing P/E at 16.9, versus 79.5 for KNSA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Cronos Group and Kiniksa Pharmaceuticals International in the same industry?
No. Cronos Group is in the Healthcare sector, while Kiniksa Pharmaceuticals International is in Health Care.